Abstract
Due to the molecular complexity of cancer, combination therapy is becoming increasingly important for better long-term prognosis with fewer side effects. To further increase the therapeutic effects, advanced drug delivery systems (DDSs), capable of simultaneously delivering multiple drugs to the site of action with specific time-programmed release profiles, are important requirements. Nanocarriers for the simultaneous co-delivery of multiple chemical drugs in combination therapy have been extensively reviewed. Here we focus on the nanotechnology enabled DDSs for the simultaneous co-delivery of therapeutic genes and chemical drugs for cancer treatment. The opportunities for this combination strategy and their challenges will be discussed.
Keywords: Cancer, co-delivery, drug delivery, liposomes, mesoporous silica nanoparticles, nanocarriers, siRNA.
Current Pharmaceutical Biotechnology
Title:Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Volume: 13 Issue: 7
Author(s): Nazia N. Choudhury and Huixin He
Affiliation:
Keywords: Cancer, co-delivery, drug delivery, liposomes, mesoporous silica nanoparticles, nanocarriers, siRNA.
Abstract: Due to the molecular complexity of cancer, combination therapy is becoming increasingly important for better long-term prognosis with fewer side effects. To further increase the therapeutic effects, advanced drug delivery systems (DDSs), capable of simultaneously delivering multiple drugs to the site of action with specific time-programmed release profiles, are important requirements. Nanocarriers for the simultaneous co-delivery of multiple chemical drugs in combination therapy have been extensively reviewed. Here we focus on the nanotechnology enabled DDSs for the simultaneous co-delivery of therapeutic genes and chemical drugs for cancer treatment. The opportunities for this combination strategy and their challenges will be discussed.
Export Options
About this article
Cite this article as:
N. Choudhury Nazia and He Huixin, Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs, Current Pharmaceutical Biotechnology 2012; 13 (7) . https://dx.doi.org/10.2174/138920112800624418
DOI https://dx.doi.org/10.2174/138920112800624418 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) The AMPAR Antagonist Perampanel Regulates Neuronal Necroptosis via Akt/GSK3β Signaling After Acute Traumatic Injury in Cortical Neurons
CNS & Neurological Disorders - Drug Targets Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo
Current Pharmaceutical Biotechnology Cannabinoid Signaling in Glial Cells in Health and Disease
Current Neuropharmacology Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets